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ABSTRACT: Phages are bacterial viruses that have gained a
significant role in biotechnology owing to their widely studied
biology and many advantageous characteristics. Perhaps the
best-known application of phages is phage display that refers
to the expression of foreign peptides or proteins outside the
phage virion as a fusion with one of the phage coat proteins. In
2018, one half of the Nobel prize in chemistry was awarded
jointly to George P. Smith and Sir Gregory P. Winter “for the
phage display of peptides and antibodies.” The outstanding
technology has evolved and developed considerably since its
first description in 1985, and today phage display is commonly
used in a wide variety of disciplines, including drug discovery,
enzyme optimization, biomolecular interaction studies, as well as biosensor development. A cornerstone of all biosensors,
regardless of the sensor platform or transduction scheme used, is a sensitive and selective bioreceptor, or a recognition element,
that can provide specific binding to the target analyte. Many environmentally or pharmacologically interesting target analytes
might not have naturally appropriate binding partners for biosensor development, but phage display can facilitate the
production of novel receptors beyond known biomolecular interactions, or against toxic or nonimmunogenic targets, making
the technology a valuable tool in the quest of new recognition elements for biosensor development.
■ INTRODUCTION
Bacteriophages, or phages for short, are bacterial viruses that
are abundant in nature but harmless to humans. Their role as
the main regulators of the microbial balance among the diverse
variety of bacteria existing in the ecosystem makes them
naturally eminent, but, owing to many interesting character-
istics, phages have also become an exceptional tool for many
biotechnological applications.1 The Greek origin of the name
bacteriophage describes them as “bacteria-eaters,”1 although
perhaps more aptly they can be defined as parasites that are
capable of infecting bacteria.2 Upon infection, the phage takes
over the biosynthetic machinery of the host cell to replicate its
genetic material and subsequently produces more than a
thousand identical phage particles.3
Naturally, a myriad of different phages exist, but, generally,
each phage particle, or virion, encloses its genome of DNA or
RNA in a protein coat, or capsid.4 Phages are ubiquitous in
nature, highly specific to bacteria, and, in addition, are
extremely robust and can withstand even harsh conditions.1
They can be classified based on their morphology, their life
cycle, and ways to propagate.1 Lytic or productive phages, such
as T4, T7, T3, and MS2 phages, are only capable of replicating
their genome, assembling the phage virions, and releasing them
by lysing and killing the host cell.4,5 Lysogenic or temperate
phages, such as λ phage, can multiply via lytic cycle or
incorporate their genome into the host cell genome where it
will produce a quiescent state.5 Filamentous phages,
characterized by their long rodlike shape, are lysogenic phages
that do not lyse their host cell but secrete the newly assembled
virions and continue the process. Filamentous phages can
infect a wide variety of Gram-negative bacteria, for example,
Escherichia coli. The most used phages include M13, fd, and f1
phages, all belonging to the Ff class, so named because they
infect the bacterial host via the tip of the F conjugative pilus.6
M13 is one of the most used phages for sensing
applications,7 and it consists of a circular single-stranded
DNA (ssDNA) genome packaged within the phage particle, a
somewhat flexible protein cylinder of about 930 nm in length
and 6.5 nm in diameter.5 The filamentous capsid consists of
the phage structural proteins, the major coat protein (pVIII),
which appears in approximately 2700 copies alongside the
virion, and the minor coat proteins, capping both ends of the
phage, pVII and pIX on one end and pIII and pVI on the other
(Figure 1A,B).5,8 The pIII is the largest and structurally most
complex of the phage proteins, and it is essential for the
infectivity because of its role in the binding to the bacterial
pilus and is necessary for the termination of the viral assembly.
The remaining six phage proteins are involved in viral
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replication and assembly.6 M13 can infect E. coli by the
attachment of the pIII to the pilus, which is encoded by the
bacterial genes carried on the F-factor. After phage binding, the
pilus retracts until the phage reaches the bacterial surface and
pIII can bind to the membrane proteins and transfer the phage
genome into the host cell.
Subsequently, the infecting phage disassembles and the coat
proteins insert into the bacterial membrane. Once inside the
bacterial cell, the phage genome is converted to double-
stranded DNA (dsDNA) by bacterial enzymes and synthesis of
new phage protein begins. Newly synthesized proteins finally
assemble around the ssDNA genome and extrude from the
bacterium. As a nonlytic phage, M13 does not kill the host cell
and the infected host continue growing and dividing.5,8
The phage structure and its mode of replication have
contributed to making phages a valuable tool for biological
research.5 Because of the natural assembly of phage virions,
they are rapid and straightforward to produce even in large
quantities in bacteria and they are fairly easy to purify in high
yields.6 Modifying the phage genome is relatively simple as
foreign DNA sequences can be inserted into the nonessentials
regions of the genome, making it a useful cloning vehicle in
biotechnology.
■ PRINCIPLES OF PHAGE DISPLAY
Phage display refers to the expression of peptide or protein
variants on the surface of the phage virion by cloning the
corresponding encoding gene as a fusion with one of the phage
coat proteins (Figure 1).5,9 This technique has been
recognized as a powerful tool to screen and select binders on
the basis of molecular recognition from phage-displayed
libraries, assemblies of about 10 billion of phage clones each
harboring a different variant of the displayed entity.6
Filamentous phages are the most common ones used for
phage display because they are rather ideal for inserting
various-length DNA segments into the genome that is
relatively small in size and accommodates well such
modifications. Moreover, cloning and construction of fusions
are facilitated by the possibility of isolating both ssDNA and
dsDNA. Being nonlytic, filamentous phages do not kill the host
cell but can be amplified in high quantities.10 On the other
hand, one of the drawbacks of using M13 for phage display is
that owing to the nonlytic propagation all of the compounds of
the virion must be exported through the bacterial inner
membrane prior to the phage assembly. Occasionally, this has
been a limitation for displaying large proteins whose size,
sequence, or folding might prevent the translocation or disrupt
the integrity of the capsid. In principle, this limitation can be
obviated by using lytic phages, such as icosahedral T4 and
especially T7, which assemble entirely in the cytoplasm.11,12
Nevertheless, based on filamentous phages, numerous
display systems have been developed using different coat
proteins for the display together with phage or phagemid
vectors. These phage display systems can be more specifically
Figure 1. (A) Structure of filamentous phage M13 which consists of a protein coat made of the major coat protein (pVIII) and the minor coat
proteins (pIII and pVI on one end and pVII and pIX on the other). The genomic DNA encoding for the coat proteins is enclosed within the
protein coat. By introducing modified segments into the genomic DNA, the phage can be engineered to display foreign peptides or proteins as a
fusion with one of the coat proteins, most commonly pIII. (B) Transmission electron micrograph of the filamentous phage M13 acquired with
negative staining using a JEOL JEM-1400PLUS instrument operating at 120 kV, with a LaB6 electron source and a GATAN US1000 CCD camera
(2k × 2k). (C) Construction of phage-displayed libraries includes generation of the DNA library encoding for the different variants and
introduction of the variable sequences in the phage DNA (typically a phage vector or phagemid system). After transforming the DNA to bacteria,
phages are amplified and will display an individual protein or peptide variants outside the virion.
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classified according to the arrangement of the coat protein
genes, which in the end affects the display valency, i.e., whether
the foreign peptide or protein is displayed on all or only part of
the copies of the coat proteins.2 The N-terminus of pIII was
the first location used for the display of a foreign peptide,13 and
it is still the most commonly used, although all five capsid
proteins have been used to this aim.6,10 The major coat
protein, pVIII, can be used for both N- and C-terminal fusions,
but only short peptides (six to eight residues) can be displayed
without disturbing the phage’s ability to replicate. Fusion with
pVIII will typically lead to multivalent display with even
thousands of copies, whereas lower valencies, usually one to
five copies per phage, can be obtained with pIII fusions.
Commonly, phage display is based on operating either on
phage or phagemid vectors.14 In the phage vector display, the
foreign DNA sequence to be displayed is cloned into the phage
genome fused with the gene of one of the coat proteins. As a
result, the phage will express the foreign entity, peptide or
protein, as a fusion with the coat protein. In some cases, for
example, if the size of the target is too large, such display may
interfere with the phage assembly and the phagemid system is
preferred. Phagemids are phage-derived vectors that do not
encode for all of the structural and functional proteins of the
phage but carry only the necessary replication origins and one
kind of coat protein that is used for the display. Phagemid
usually contains an antibiotic resistance gene and two origins
of replication, a plasmid replication origin that allows them to
replicate in a high copy number in the host cell and a
filamentous phage replication origin that is activated once the
phagemid-bearing cell is superinfected with the helper phage.
Thus, the phagemid by itself can replicate within a bacterial
cell and maintain itself as a plasmid, but it is not able to finish
the assembly of phage particles independently. Only when a
helper phage vector containing the genetic elements for phage
packing is present, the host cell harbors both the phagemid and
the helper phage genome, and thus, phage particles can be
produced. In fact, superinfection results in two types of
infective virions, particles carrying the helper phage DNA and
particles with the phagemid DNA.6,15
Generally speaking, the phagemid vectors are preferred,
especially when displaying entire proteins or antibody
fragments. As the size of the phagemid is considerably smaller
than that of the phage vector, they are easier to manipulate,
maintain, and propagate, and they usually allow higher
transformation efficiencies and improved genetic stability.
Moreover, cloning is relatively simple in comparison with
phage vectors that have a somewhat complex structure with
overlapping genes, promoters, and terminators.10 In addition,
the phagemid system is required if a monovalent display is
desired. Nevertheless, the phagemid system requires an
additional infection with a helper phage to provide all of the
proteins needed to make ssDNA and new virion particles.8 The
helper phage usually has a modified packing signal to favor the
packing of the phagemid,16 and further modifications can
allow, for example, multivalent display or inhibition of wild-
type phage infection with trypsin-cleavable pIII display.17,18
The tryptic helper phage (KM13) is sensitive to trypsin and
loses its infectivity when incubated with this protease.
Therefore, trypsin treatment after the selection can eliminate
the majority of the helper phages that do not display the
foreign peptide of interest. In other words, only those phages
carrying the fusion protein can maintain their infectivity and
continue to propagate in the bacterial host.5,6
■ PHAGE-DISPLAYED LIBRARIES
Peptide Libraries. Phage-displayed libraries are made of
billions of phage clones, each one carrying a different foreign
DNA insert and therefore displaying a unique peptide or
protein sequence on its surface (Figure 1C).2 The foreign
DNA sequence coding for the displayed entity can be derived
from a natural source, or it can be deliberately designed and
synthesized chemically.6
The use of peptide libraries is perhaps inferior to antibody
libraries, but nevertheless, they have been widely used for
various applications, for example, for epitope mapping,19
immunotherapy,20 antiviral research,21 vaccine development,22
and protein−protein interaction studies.23 Moreover, peptides
can provide information about interactional motifs, epitopes or
binding sites of antibodies and other proteins. Phage-displayed
peptides can also be useful intermediates in the development
of small-molecule drugs.24 Remarkably, peptides can be
isolated against almost any protein target, including, for
example, antibodies, enzymes, receptors, transcription factors,
and protein interaction domains.6 Experience has shown that
peptides identified by phage display commonly bind to protein
functional sites rather than randomly or nonspecifically to the
surface of the target. Such binding sites are often grooves or
depressions in the protein surface with exposed hydrophobic
groups, making them suitable for specific target binding.6 If the
peptide binds to the functional site of the target protein, it will
also most likely inhibit binding of others to the same site.
Taking advantage of this feature peptides have been used as
surrogate ligands in a variety of competition-based assays for
drug discovery.6 Similarly, antibody binding peptides have
been applied as epitope mimics in competitive immuno-
assays.25
Many peptide libraries are made by joining the DNA
sequences coding for the peptide directly into the phage
genome at, or near, the N-terminus of gIII. As a result,
potentially five copies of peptide−pIII fusions are displayed at
one end of the phage particle. Fusion to the gVIII can result in
more than 2000 copies of the peptide per phage. It should be
noted that as the strength of the binding is defined not only by
the affinity of the interaction but also by the avidity, i.e., the
overall strength of the binding, which is affected by the number
of binding sites, may have substantial effects.1 Thus, the
multivalent nature of the display will have significant avidity
effects and potentially low-affinity binders might end up
selected due to the high avidity.24 The size of the peptide is
limited in such systems but can be increased if a phagemid
system is used. Moreover, the phagemid system allows
reducing the avidity effects by a monovalent display. The
diversity of peptide libraries, in terms of the number of distinct
peptide sequences, is usually limited by bacterial trans-
formation efficiency. Typically, the diversity of peptide libraries
vary between 107 and 109 phages. Thus, the size of completely
randomized peptides (for example, 20 different codons, at n
different positions) is limited to n = 6−8. Despite these
limitations, also longer peptides, although incomplete in terms
of nucleotide randomization, have been used to construct
libraries with sufficient variability.2,24
Random peptide libraries can be derived by oligonucleotide-
directed mutagenesis from “degenerate” oligonucleotides that
are synthesized chemically by adding mixtures of nucleotides
to a growing nucleotide chain.2,6 Random peptide libraries can
be described as naiv̈e, in the sense that they are designed to be
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as unbiased as possible and, thus, they can provide specific
binders for many different targets. However, selections from
naiv̈e libraries often result in binders with low or mediocre
affinities, especially if the diversity of the library is not
sufficient.26 Randomness in the sequence can be introduced at
the nucleotide level varying all of the nucleotides of the codons
(NNN), resulting in highly biased diversity since some amino
acids are represented by several codons and furthermore three
codons are stop codons. Thus generally, degeneracy at the
codon level is preferred as it gives a less biased representation
of the amino acids. In fact, even less redundant diversity where
only the third position of the codon is allowed to vary either as
G/C or G/T (NNK or NNS) is sufficient to cover all of the 20
amino acids.6
In some cases, randomization is restricted to certain regions,
thus creating a constrained library opposed to an uncon-
strained one. In general, constrained peptide libraries present
less three-dimensional shapes than an unconstrained library
and, therefore, the probability for target binding is reduced.
However, those with appropriate conformations may possess
far higher affinities than any unconstrained peptide because the
loss in entropy on target binding is likely less than for
unconstrained peptide.2,26 Common constraint on displayed
peptides is a disulfide bond between two cysteine residues at
fixed positions in an otherwise random sequence, resulting in
cyclic peptides. Similarly, coordination bonds between
histidine residues and metal ions can be used as constraints.2,26
Alternative, constrained peptides can be presented in the
context of a protein scaffold, such as α-helices, β-sheets, or
other secondary structure elements. In a sense, antibody
libraries actually entail a protein scaffold where specific regions
responsible for the antigen binding have been randomized.
Antibody Libraries. Although the first use of phage display
focused on peptides, antibody libraries have been arguably the
most successful use of this technology and have led to the
discovery of antibodies with affinities comparable to those
obtained by hybridoma technology.9,27 In fact, alongside with
the development of monoclonal antibodies using hybridoma
technology28 and the isolation and cloning of antibody genes
to enable expression of antibody fragments in bacteria,29,30 the
generation of antibody libraries by phage display can be
considered as one of the groundbreaking methods for the
antibody discovery.
Antibody libraries can be constructed from natural sources
by isolating the B cells of a source animal that has been
immunized with the target antigen and using the isolated
antibody genes to create the antibody library.31 These kind of
libraries have a strong bias toward the antigen, and even a
modest-sized library can be sufficient to isolate specific binders.
However, construction of a separate immunized library is
needed for each antigen, although immunization with several
antigens simultaneously is also possible.32 Most of these
libraries are produced from mouse,33−37 but also other animals,
such as chicken,38,39 rabbit,32,40 sheep,41 monkey,42 camel,43
and shark,44 have been used. Additionally, immunized human
libraries have been made using blood from patients naturally
infected with viruses or parasites.5,45
On the other hand, naiv̈e antibody libraries can be
constructed completely in vitro resulting in nonimmunized,46
synthetic,47 or semisynthetic libraries.48 The use of synthetic
repertoires bypasses the need to isolate antibody genes and
allows generating sequences with predefined properties, or
using optimal framework sequences.49 Nonimmunized libraries
are a result of rearranged antibody genes isolated from B cells
of healthy individuals that have not been intentionally
immunized. Semisynthetic and combinatorial libraries combine
natural and synthetic sequences. Such libraries are usually
constructed by introducing synthetic diversity into a naiv̈e
library by polymerase chain reaction (PCR) assembly of
germline genes, or by recombination of in vivo formed
complementarity-determining regions (CDRs).9 Synthetic
libraries are constructed entirely in vitro using oligonucleotides
to introduce diversity into the CDRs. While antibodies with
mediocre affinities are readily screened from relatively small
naiv̈e or synthetic libraries, in general, for isolating high-affinity
binders, the diversity of the library becomes significant.9 In
fact, studies have shown a linear correlation between the library
size in terms of diversity and the highest affinity that has been
isolated, meaning that, in particular, in the case of naiv̈e or
synthetic libraries, the size of the library must be large enough
to increase the probability of finding a given antibody and
enhance the quality of the antibody.50
Other Functional Domains and Scaffolds. Phage
display technology also offers a means to explore other
nonantibody protein binders. Functional protein domains refer
to short polypeptide chains that are capable of creating a three-
dimensional structure required for a defined functional
activity.5 For example, affibodies are engineered single-domain
proteins, in which a functional scaffold has been derived from
protein A.51 Affibody molecule libraries have been constructed
by combinatorial randomization of the amino acids in the
scaffold and used to select binders by phage display.52,53 Other
binding scaffolds include, for example, anticalins,54,55 DAR-
Pins,56 knottins,57 atrimers, and fynomers,58 which all can be
selected using phage display, although these binders have been
less used in biosensing applications.
■ IN VITRO AFFINITY SELECTIONS
Individual clones from phage-displayed libraries theoretically
can be directly screened for target binding, for example, by
immunoassays, in a manner resembling screening of synthetic
or chemical libraries that must be screened compound by
compound. However, screening of libraries consisting of
millions to billions of different clones is limited by the number
of clones that can be examined.9 To efficiently isolate specific
binders, the library needs to be coupled to a technology that
provides the means to carry out selections from these
repertoires. In vitro display technologies, which basically
mimic the natural in vivo process of antibody production,
have enabled such proficient enrichment and selection of
binders in a rapid and controllable manner. The essence of the
display technologies resides in the physical linkage between the
phenotype of the phage displaying the protein or peptide on
the surface and the genotype encoding for that entity packaged
as the genetic information within the same phage particle. This
link enables selection of phage-displayed libraries and powerful
enrichment by selective propagation of the individuals with the
desired properties.9 Thus, a single displayed entity, be it a
peptide, protein, or antibody fragment, of the desired trait, can
be captured from a pool of billions of variants and its gene can
be amplified and used for another selection round or whatever
downstream purpose might be desired.8
Although phage display is the most renowned technique for
screening libraries,13,59 also other display methods, including
cell surface display using bacteria,60 yeast,61 or mammalian
cells,62 as well as cell-free systems, such as ribosome display,63
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have been successfully applied to screen antibody libraries.
Although less popular than phage display technology, these
methods present some advantages, such as the ability of yeast
cells to express complex proteins that require post-translational
modifications or the possibility to create larger libraries using
cell-free methods that are not restricted by the bacterial
transformation efficiency.64
The process of in vitro affinity selection, whether it is based
on phage or other display systems, commonly includes (I) the
generation of genotypic diversity by constructing protein or
peptide libraries that consist of millions or billions of different
variants; (II) the display method that creates a physical link
between the expressed protein variant and the gene coding for
it; (III) the application of selective pressure to screen for
target-specific binders, and, finally, (IV) the amplification of
the selected variants.9 Remarkable features of in vitro selection
technologies include the possibility of defining the selection
conditions carefully, the potential for high-throughput
applications, and further improvement of selected binders by
various protein engineering methods, for example, to achieve
better affinity or stability, to reduce unwanted cross-reactivities,
or to add tags for further purification or immobilization.65−67
These systems provide immediately the genes and correspond-
ing DNA sequences of the clones selected against the specific
target. Simple subcloning can allow presenting modifications or
adding functionalities, such as purification tags or fusions to
enzymes or fluorescent proteins.65 Moreover, also convention-
ally challenging targets, such as toxic or nonimmunogenic
molecules, have been successfully used.68,69
The screening process of phage-displayed libraries, com-
monly known as panning, includes introducing the phage-
displayed library to the target captured to a solid surface,
washing to remove the unbound and nonspecifically bound
phages, elution of the bound phages, and amplification of the
eluted phages through bacterial infection (Figure 2A). Ideally,
only one round of selection is required, but as nonspecific
binding limits the enrichment in one selection round, in most
cases, three to five iterative rounds of selection and
amplification are performed to select individual binders.
A variety of modifications in the panning protocol and
details for improved selections have been described for the
identification of high-affinity binders from phage-displayed
libraries. Generally, the experiment can be designed to
maximize either phage capture or affinity discrimination.
While effective capture is best used for the first selection
round, the conditions can be modified in the later rounds to
produce better affinity discrimination.5 The early rounds of
selection can be considered as the most important ones
because any bias or loss of diversity during the first round will
be amplified in the subsequent rounds. Since the number of
potential binders is low among the highly diverse library, a
common practice is to maximize the capture of all interesting
clones. Later, when enrichment of selective clones is seen, and
the diversity is reduced in the subsequent rounds, stringency
can be increased by decreasing the target concentration or
increasing the number or length of the washes.6
The selections are commonly carried out in solution or at a
solid phase. Most frequently, the target is directly immobilized
on a solid support, such as an immunotube, a bead, or a
microtiter plate. This enables the separation of bound and
unbound phages simply by washing the support.6 Small
molecules, which cannot be directly immobilized, are often
conjugated to a carrier protein, or chemically coupled to a
linker like biotin. For binding in solution, a biotinylated target
is incubated with the phages in solution, after which the target
bound phages are captured by streptavidin, for example, using
magnetic beads.5
Because binding is an equilibrium reaction where the
amount of the binder−target complex formed is determined
by the affinity and the concentrations of the binder and the
target, the amount of the target used for the selections is one of
the critical factors in the process. Theoretical models suggest
that high-affinity binders should be selected with a target
concentration lower than the dissociation constant (KD), but
often target excess is used, in particular, in the first rounds, to
allow capture of a higher fraction of the phage population and
decrease the risk of losing the rare high-affinity binders.70
However, by using limited and decreasing amounts of the
target in the later rounds, the selection favors high-affinity
Figure 2. Selection of affinity binders from a phage-displayed library. (A) Selection process consists of binding, washing, elution, and amplification
steps, which are usually repeated to three to five times to enrich target-specific binders. (B) Target specificity of individual clones can then be
determined by screening the monoclonal clones from single colonies in enzyme-linked immunosorbent assay (ELISA), and the positive clones can
be identified by DNA sequencing.
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binders.9 Additionally, if multivalent display is used, avidity will
play a significant role in the binding and seemingly good
binders, with actually low affinity, might be selected due to
avidity effects. When selection of high-affinity binders is
desired, monovalent display is thus preferred,6 although the
use of a controlled density of the target during the selections
can reduce avidity effects, favoring one-to-one binding
interactions even with multivalent displays.24
On the other hand, also, the washing step is of great
importance. Typically, affinity, in terms of the KD that is the
ratio of the association (kon) rate to the dissociation rate (koff),
can be improved by removing phages with fast dissociation
rates in the washing step. The number and length of the
washings can be thus optimized to select high-affinity binders.
Short incubation times, short washes, low target concentration,
and a decreased number of input phage might favor the
selection of clones with fast binding.9,71 Finally, in the elution
step, bound phages are typically eluted by addition of an acid
or a base to break the binding interactions. If such treatment is
not efficient enough, it will result in the loss of high-affinity
binders. On the contrary, the application of too harsh
conditions might affect the infectivity of the phage and have
consequences in the amplification step. Alternatively, elution
can be done by competition, i.e., by adding an excess of the
free target to the selections or by cleavage of phages that
include a specific protease cleavage site between the phage and
the displayed binder.5
One of the remarkable features of phage display is the
possibility to carefully determine the selection conditions
favoring the selection of binders, for example, with fast kinetics
or improved biophysical properties. For instance, thermody-
namically or otherwise stable variants have been selected by
subjecting the library to elevated temperature,72 low pH, or
protease treatment.73 Heat denaturation can be also used to
select aggregation-resistant proteins or identify features that
promote or prevent protein aggregation.74,75 Finally, it should
be also noted that the amplification step is susceptible to
artifacts such as biased production of clones that are capable of
growing faster than an average clone.6 Thus, it is not only the
affinity of the binder that determines which clones enrich but
also the toxicity of the specific clones to the bacterial host, the
solubility, folding efficiency, and stability of the expressed
variant may contribute to the outcome of phage display.
The outcome of any selection process is a mixture of clones
with different target-binding properties. Screening of individual
clones, typically by phage-based immunoassays (for example,
enzyme-linked immunosorbent assay, ELISA), is needed to
evaluate their target-binging capabilities. Finally, DNA
sequencing of selected clones can be used as a guideline to
define at what stage to screen the library and identify the
individual protein or peptide variants (Figure 2B).9 Recent
developments in the automation of the selection process have
enabled rapid screening, for example, for several targets
simultaneously. Moreover, screening robots allow testing of
thousands of different binders9 and protein microarrays can
prove useful for high-throughput analysis of the specificity and
affinity.76
In continuation of mimicking the natural selection process,
similarly to affinity maturation in vivo, in which the immune
response is capable of producing antibodies with an increased
affinity,77 a variety of in vitro techniques can be used to
improve the affinity and specificity of the binders. The process,
known as in vitro affinity maturation, comprises a variety of
mutagenesis strategies that have been used to construct
second-generation libraries, based on desired characteristics
of the parental peptide or antibody, with some fixed or biased
sequences. Various techniques used include random muta-
genesis using DNA modifying enzymes or error-prone PCR,
introducing mutations to certain areas or residues of the
antibody, usually in the variable region and the hypervariable
loops, for example, by oligonucleotide-directed mutagenesis.
Also, DNA recombination, including using natural evolution or
recombination of the target gene, can be used to recombine
homologous segments to emphasize the desired property or to
shuffle heterologous genes to create new diversity.6,78
■ RECOGNITION ELEMENTS FOR BIOSENSORS
The importance of monitoring and regulating various bio-
logically significant molecules in many different disciplines,
such as clinical chemistry, environmental protection, drug
discovery, forensics, and food industry, has incited the
development of reliable sensing devices capable of accurate
analysis.79−84 Biosensors can provide rapid, sensitive, low-cost,
real-time, and on-site analysis with compact and low-power
devices. Owing to their appealing advantages, they have
emerged as one of most interesting approaches to overcome
the limitations of currently applied conventional methods, for
example, for environmental monitoring, food analysis, and
point-of-care medical applications.85 The high specificity and
sensitivity of biomolecular recognition, which is typically
driven by a concert of many weak interactions, is the
cornerstone of biosensor development, as the binding event
has a direct effect on the accuracy of the method.1,86 The
recognition element of choice must be able to detect the target
analyte even at low concentrations, and moreover, it ought to
differentiate it from other similar molecules that might be
present in the sample simultaneously.
Initially, biosensors were mainly based on enzymes and
polyclonal or monoclonal antibodies as recognition elements,
but in recent years, phage display has become a useful tool to
identify new biorecognition elements for particular targets.1
For example, the use of recombinant antibodies has several
advantageous characteristics in comparison with conventional
polyclonal and monoclonal antibodies. To begin with, the
small size of antibody fragments is usually accompanied by a
decrease of nonspecific binding often caused by the Fc region
of the intact antibody and the possibility to immobilize the
antibodies at a higher density.87 Moreover, unlike full-length
antibodies, recombinant antibody fragments can be propagated
in bacteria, such as E. coli, which significantly lower the cost of
production as no specialized cell culture facilities for
hybridoma cell lines are needed.88,89 On the other hand,
phage display also offers the possibility of selecting various
other bioinspired recognition elements,25 such as peptides or
other binding proteins and scaffolds, which might provide
further advantages compared to antibodies. In vitro selections
by phage display facilitates the production of novel receptors
beyond known biomolecular interactions, or against toxic or
nonimmunogenic targets, or even using whole cells as the
target.1
Wild-type or genetically modified phages, as well as
individual phages displaying a particular protein or peptide
of interest, can be directly used as biorecognition elements as
has been reported in a myriad of phage-based biosensors.90,91
Biosensors for pathogen detection can be based on the
inherent ability of the phages to bind to their target
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pathogen,92 or phages can be utilized as a means to display the
biorecognition element, be it an antibody fragment, a peptide,
or any other protein binder. Antibody fragments, mostly single-
chain variable fragments (scFv), have been widely used for
various targets in biosensing applications where their small size
in comparison with the intact IgG can be of advantage.87 Other
common recombinant antibody fragments include the heavy-
chain antibodies (VHH), also known as nanobodies or single-
domain antibodies, which have gained significant attention due
to their extraordinary structure that is completely devoid of the
light chains.66,93 Alternatively, short peptides originating from
phage-displayed libraries have been introduced as an
interesting alternative for the development of new biosensing
platforms because of their small size and cost efficiency.
Peptides often suffer from a poor or mediocre affinity in
comparison with antibodies, which might limit their use in
certain applications. Nevertheless, although the interactions of
an individual peptide with its target might be weak, stronger
binding has been achieved by multivalent display on the phage
particles, resulting in significant avidity effects. Various
recognition elements have been applied to biosensors in
their phage-displayed format, but, on the other hand, once an
individual target-specific phage has been identified, the phage
itself becomes expendable. After identification, the recognition
element thus may also be subcloned into an expression system
for large-scale production and different downstream applica-
tions. Alternatively, short peptides can also be chemically
synthesized via solid-phase peptide synthesis.
Recombinant antibodies and short peptides originating from
phage-displayed libraries have been reported in various
biosensor applications, most notably in ELISA and surface
plasmon resonance (SPR).1 Furthermore, numerous different
phage-based sensing schemes have been published recently
using other transduction techniques, for example, fluorescence,
Raman, quartz crystal microbalance, magnetoelastic, and
electrochemical techniques. In this context, we will introduce
a few interesting and recent applications for different kinds of
targets (Table 1), but for a comprehensive overview of phage-
based biosensors, we refer the reader to recent review
articles.7,91,92,94
Label-free techniques, such as SPR, are often able to provide
simple detection of the target binding to the recognition
element immobilized on the sensor surface. Such measure-
ments enable real-time monitoring of the binding reaction and
can be used to evaluate also the kinetic and thermodynamic
parameters of the molecular recognition process.95,96 SPR
biosensors for the detection of whole cells such as Listeria
monocytogenes97 and Salmonella98 have been reported using
phage-displayed antibodies or peptides, enabling detection of
the cells in the range of 106−107 cfu mL−1. Another label-free
biosensor based on electrochemical impedance spectroscopy
and specific peptides selected from a landscape phage library-
enabled99 detection of cancer cells down to 79 cells mL−1.
Phages have also arisen as an interesting option for
multifunctional structures. For example, Staphylococcus aur-
eus-specific pVIII fusion protein identified by phage display was
used in combination with bifunctional gold nanoprobes for
label-free, rapid, and sensitive colorimetric detection of
pathogens.100 For optical detection of cancer cells, phage
fusion proteins were combined with Au@Ag heterogeneous
nanorods in a self-assembled biomimetic nanostructure.101 In a
different approach, phages displaying a target-specific peptide
were assembled with silver nanoparticles to identify U937 cells
by surface-enhanced Raman spectroscopy (SERS).102
Antibody fragments originating from phage-displayed
libraries have been reported for various protein targets, such
as scFv against dengue virus nonstructural protein103 or single
variable domain antibodies (VHH) from camel against prostate-
specific antigen (PSA) that were applied to PSA detection by
SPR.104,105 Also, various peptide binders against protein targets
have been selected by phage display, for example, for the
development of biosensors applied to the analysis of protein
targets, such as cholera toxin,106 troponin I,107 prostate-specific
antigen,108 norovirus capsid proteins,109,110 alanine amino-
transferase,111 and sepsis112 or dengue fever biomarkers.113
Recently, a SERS biosensor based on M13 phages that display
cysteine-rich peptides on the pVIII was developed for triplex
assay in sepsis diagnosis. The assays on magnetic templates
with picomolar detection limits was described as a promising
alternative for early clinical diagnosis of sepsis.114
Small-molecule targets, haptens, which might be challenging
targets for antibody development, have been also successfully
used to develop antibodies by phage display. The selection and
application of scFvs against various targets, such as
morphines,115 mycotoxins,116−118 and environmental toxins
including microcystins,119,120 have been reported. For such
applications, soluble antibody fragments are commonly
expressed in E. coli after identifying the target-binding clones
Table 1. Recent Examples of Biosensors Based on Recognition Elements Discovered by Phage Displaya
target analyte recognition element phage library transduction method sensitivity (LOD) ref
varcinoma cells (SW620) phage-displayed peptide f8/8 landscape library EIS 79 cells mL−1 99
Staphylococcus aureus pVIII fusion protein f8/8 landscape library absorbance 19 CFU mL−1 100
Salmonella phage-displayed peptide Ph.D.-12140 SPR 8.0 × 107 CFU mL−1 98
cholera toxin (CTX-B) synthetic peptide Ph.D.-12 LSPR 1.89 ng mL−1 (LSPR) 106
SERS 3.51 pg mL−1 (SERS)
noroviral capsid protein (rP2) synthetic peptide Ph.D.-12110 EIS 1.44 μg mL−1 (99.8 nM) 109
dengue fever biomarker NS1 phage-displayed peptide Ph.D.-12 EIS 0.025 μg mL−1 113
flame retardant (DBDE) synthetic peptide Ph.D.-12 CNT-FET 1 fM 130
prostate-specific antigen (PSA) nanobody immunized (alpaca) DPV 0.08 ng mL−1 141
T-2 toxin Fab and anti-IC Fab immunized and naiv̈e TR-FRET 0.38 ng mL−1 121
aAbbreviations: anti-IC, anti-immune complex; CFU, colony forming unit; CNT-FET, carbon nanotube field-effect transistor; DBDE,
decabrominated diphenyl ether; DPV, differential pulse voltammetry; EIS, electrochemical impedance spectroscopy; Fab, antibody fragment
antigen binding; LOD, limit of detection; LSPR, localized surface plasmon resonance; Nb, nanobody; Ph.D.-12, combinatorial library of random
12-mer peptides by New England Biolabs; scFv, single-chain fragment variable antibody fragment; SERS, surface-enhanced Raman spectroscopy;
TR-FRET, time-resolved fluorescence resonance energy transfer.
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by phage display. For example, HT-2 mycotoxin was analyzed
using antibody fragments selected from an immunized library
together with anti-immune complex antibodies from a naiv̈e
phage-displayed library.121 The noncompetitive immunoassays
for HT-2 analysis enabled detection of the toxin with excellent
sensitivity and specificity. In a different approach, scFv for
2,4,6-trinitrotoluene was conjugated to luminescent quantum
dots to develop solution-phase nanoscale sensing assemblies
based on fluorescence resonance energy transfer (FRET) for
the specific detection of the explosive in aqueous environ-
ments.122 Also, some applications of nanobodies for small-
molecule detection have been reported recently, mainly for
mycotoxins.123−126 Nanobodies have some advantageous
characteristics beyond their small size, most notably excellent
shelf life and high stability even in harsh conditions or at
elevated temperatures.66,127
Short peptides originating from phage-displayed libraries
have also been reported for small-molecule detection. For
example, for the detection of herbicide glyphosate, an
oligopeptide was identified from a phage display library and
the synthetic was immobilized onto the SPR gold sensor chip
for the analysis.128 Alternatively, bisphenol A was detected by
differential pulse voltammetry (DPV) and a cysteine-flanked
heptapeptide as the recognition element.129 For the detection
of a flame retardant polybrominated diphenyl ether, a peptide
receptor was integrated with a carbon nanotube field-effect
transistor for the selective detection of the target in the
femtomolar range.130 Interestingly, phage display has also been
employed to select binders against inorganic materials, such as
ZnS,131 CdS,132 ZnO,133 and TiO2,
134 widening the range of
biosensor applications based on phage assemblies and phage−
nanomaterial complexes.135
■ FUTURE PERSPECTIVES
Since the first description of phage display more than 30 years
ago, various applications have demonstrated the significance of
the technology and it has been established as a valuable and
remarkably versatile tool in many disciplines for selecting
affinity binders and exploring interactions between proteins,
peptides, and small-molecule ligands, making significant
contributions to the study of molecular recognition.5,6
Among the striking success stories of phage display, peptide
libraries have been used for instance to develop low-nanomolar
peptide agonists136,137 and antibody libraries have opened the
way for the generation of human antibodies against various
targets, including more than 60 antibodies obtained from
phage-displayed libraries that have been approved for human
therapy.138,139
For biosensor development, phage display can offer a new
means to discover recognition elements, even beyond natural
and known biomolecular interactions. In vitro selection of
novel affinity binders allows tight control over the selection
conditions as well as the use of conventionally challenging
targets, or even whole cells. Although immunized libraries
often result in excellent affinities, synthetic and naiv̈e phage
libraries, in particular, represent an intriguing alternative as
they can be used to select antibodies against virtually any
target, at least theoretically, within couple of weeks without the
need of animal immunization. Moreover, since the library
selections are solely based on affinity, also toxins and
biologically active or threatening targets can be directly used
unlike when animal immunization is required.
One of the important factors when choosing a recognition
element for biosensors is the shelf life and stability of the
receptor. While conventional antibodies might suffer from
poor stability, phage display can be used to select folded and
thermodynamically stable proteins from libraries. For example,
camel or shark antibodies (and especially VHH camel
nanobodies) have gained great attention in the last years for
their reduced size, high stability, improved solubility, and
improved solvent compatibility, which make them of special
interest for the development of biosensors.
Often after identifying the ideal recognition element, the
biosensor is constructed using the recombinant or synthetic
affinity element. However, also phage particles by themselves
can be integrated into the biosensing devices with emerging
materials and nanostructures. In this sense, phages can be
magnetically or metallically combined and then bioinspired
analytical nanodevices or sensing materials can be constructed
with tunable sensor properties for the detection of target
molecules. On the other hand, application of phages for in vivo
biosensing systems (for example, for medical diagnosis,
foodborne control, etc.) should be preceded by toxicity tests
to avoid any safety or social concern because of their viral
nature.
Although advances in this field have been impressive in the
last few years, the future of phages as sensing elements will
require a multidisciplinary collaboration between experts from
different scientific fields to boost their applications at the level
of other usual biorecognition elements. Therefore, we can
expect due to phage display overall trajectory and versatility
since its discovery a whole generation of phage-derived
biosensing devices in the near future.
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